JCR Pharmaceuticals Co., Ltd.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Public

Established: 1975-01-01

Employees: 934

Market Cap: -

Website: http://www.jcrpharm.co.jp

Clinical Trials

An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB

Phase 1

Not yet recruiting

Conditions: Mucopolysaccharidosis III-B

Interventions: Drug: JR-446

First Posted Date: 2024-07-05

Last Posted Date: 2024-07-05

Lead Sponsor: JCR Pharmaceuticals Co., Ltd.

Target Recruit Count: 10

Registration Number: NCT06488924

Locations: 🇯🇵
National Center for Child Health and Development, Tokyo, Japan
🇯🇵
Hiroshima University Hospital, Hiroshima, Japan
🇯🇵
University of the Ryukyus Hospital, Okinawa, Japan

Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA

Phase 1

Recruiting

Conditions: Mucopolysaccharidosis III-A

Interventions: Drug: JR-441

First Posted Date: 2023-10-23

Last Posted Date: 2023-10-23

Lead Sponsor: JCR Pharmaceuticals Co., Ltd.

Target Recruit Count: 12

Registration Number: NCT06095388

Locations: 🇩🇪
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in Mucopolysaccharidosis Type II (Hunter Syndrome) Subjects

Phase 3

Conditions: Mucopolysaccharidosis II

Interventions: Drug: JR-141

First Posted Date: 2022-10-26

Last Posted Date: 2024-12-17

Lead Sponsor: JCR Pharmaceuticals Co., Ltd.

Target Recruit Count: 80

Registration Number: NCT05594992

Locations: 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
🇧🇷
Instituto de Genética e Erros Inatos do Metabolismo, São Paulo, Brazil
🇫🇷
Hôpital Femme Mère Enfant, Bron, France

and more 3 locations

A Phase III Study of JR-141 in Patients with Mucopolysaccharidosis II (STARLIGHT)

Phase 3

Recruiting

Conditions: Mucopolysaccharidosis II

Interventions: Drug: JR-141
Drug: Idursulfase
Drug: JR-141 or Idursulfase

First Posted Date: 2020-10-05

Last Posted Date: 2024-12-19

Lead Sponsor: JCR Pharmaceuticals Co., Ltd.

Target Recruit Count: 80

Registration Number: NCT04573023

Locations: 🇮🇱
The Chaim Sheba Medical Center, Ramat Gan, Israel
🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 24 locations

An Extension Study of JR-171-101 Study in Patients With MPS I

Phase 1

Active, not recruiting

Conditions: Mucopolysaccharidosis I

Interventions: Drug: JR-171 (lepunafusp alfa)

First Posted Date: 2020-07-01

Last Posted Date: 2024-08-16

Lead Sponsor: JCR Pharmaceuticals Co., Ltd.

Target Recruit Count: 14

Registration Number: NCT04453085

Locations: 🇯🇵
National Hospital Organization Kokura Medical Center, Kitakyushu, Japan
🇯🇵
Osaka Metropolitan University Hospital, Osaka, Japan
🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States

and more 3 locations

An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II

Phase 2

Active, not recruiting

Conditions: Mucopolysaccharidosis II

Interventions: Drug: JR-141

First Posted Date: 2020-04-16

Last Posted Date: 2024-03-15

Lead Sponsor: JCR Pharmaceuticals Co., Ltd.

Target Recruit Count: 27

Registration Number: NCT04348136

Locations: 🇯🇵
Fukui Clinical site, Fukui, Japan
🇯🇵
Fukuoka Clinical site 2, Fukuoka, Japan
🇯🇵
Fukuoka Clinical site, Fukuoka, Japan

and more 17 locations

A Study of JR-171 in Patients With Mucopolysaccharidosis I

Phase 1

Completed

Conditions: Mucopolysaccharidosis I

Interventions: Drug: JR-171 (lepunafusp alfa)

First Posted Date: 2020-01-13

Last Posted Date: 2022-12-14

Lead Sponsor: JCR Pharmaceuticals Co., Ltd.

Target Recruit Count: 19

Registration Number: NCT04227600

Locations: 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇯🇵
Fukuoka Children's Hospital, Fukuoka, Japan

and more 3 locations

An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II

Phase 2

Active, not recruiting

Conditions: Mucopolysaccharidosis II

Interventions: Drug: JR-141

First Posted Date: 2018-10-17

Last Posted Date: 2023-06-23

Lead Sponsor: JCR Pharmaceuticals Co., Ltd.

Target Recruit Count: 19

Registration Number: NCT03708965

Locations: 🇧🇷
Grupo de Pesquisa Clínica em Genética Médica - HCPA, Porto Alegre, Brazil
🇧🇷
Igeim - Unifesp, São Paulo, Brazil

A Study of JR-141 in Patients With Mucopolysaccharidosis II

Phase 2

Completed

Conditions: Mucopolysaccharidosis II

Interventions: Drug: JR-141

First Posted Date: 2018-06-26

Last Posted Date: 2022-11-14

Lead Sponsor: JCR Pharmaceuticals Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT03568175

Locations: 🇯🇵
Osaka Clinical site, Osaka, Japan
🇯🇵
Saitama Clinical site, Saitama, Japan
🇯🇵
Fukui Clinical site, Fukui, Japan

and more 16 locations

A Study of JR-141 in Patients With Mucopolysaccharidosis II

Phase 2

Completed

Conditions: Mucopolysaccharidosis II

Interventions: Drug: JR-141

First Posted Date: 2017-12-02

Last Posted Date: 2022-11-14

Lead Sponsor: JCR Pharmaceuticals Co., Ltd.

Target Recruit Count: 18

Registration Number: NCT03359213

Locations: 🇧🇷
Igeim - Unifesp, São Paulo, Brazil
🇧🇷
Grupo de Pesquisa Clínica em Genética Médica - HCPA, Porto Alegre, Brazil

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy